Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 2:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–22 of 22 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Disease modifying treatment (DMT) Clear all
Completed No phase listed Observational

Biogen Multiple Sclerosis Pregnancy Exposure Registry

NCT01911767
View directory record Official record
Conditions
Multiple Sclerosis, Exposure During Pregnancy
Interventions
Dimethyl fumarate, Peginterferon beta-1a
Drug
Lead sponsor
Biogen
Industry
Eligibility
Female only
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 2, 2026, 2:58 AM EDT
Completed No phase listed Observational

A Study of Treatment Patterns and Annualized Relapse Rate in Multiple Sclerosis Patients Who Escalate Versus Continue Disease-Modifying Therapies Following Relapse

NCT07743281
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
753 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 2, 2026, 2:58 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Sema 4A as a Marker for Inflammatory Disease in Multiple Sclerosis

NCT05077956
View directory record Official record
Conditions
Relapsing Multiple Sclerosis, Multiple Sclerosis
Interventions
Cerebrospinal and Blood Serum Semaphorin 4A Levels
Diagnostic Test
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years to 55 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 7, 2023 · Synced Oct 2, 2026, 2:58 AM EDT
Recruiting No phase listed Observational

Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)

NCT05658497
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Diroximel Fumarate, Avonex, Tysabri, Dimethyl Fumarate
Drug · Biological
Lead sponsor
Biogen
Industry
Eligibility
Female only
Enrollment
908 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
2
States / cities
Aurora, Colorado • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 2, 2026, 2:58 AM EDT
Completed No phase listed Observational

A Real-world Study of Disease-modifying Therapy Treatment Outcomes in Patients With Spinal Muscular Atrophy

NCT07403214
View directory record Official record
Conditions
Muscular Atrophy, Spinal
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
4,805 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 2, 2026, 2:58 AM EDT
Terminated Phase 1 Interventional Results available

Fecal Microbiota Transplantation (FMT) of FMP30 in Relapsing-Remitting Multiple Sclerosis

NCT03594487
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
FMP30 Donor Stool, Fecal Microbiota Transplantation (FMT) of FMP30 Donor Stool, Observational Control
Drug · Procedure · Other
Lead sponsor
Jeffrey Gelfand
Other
Eligibility
18 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 2, 2026, 2:58 AM EDT
Completed No phase listed Observational

A Study of Dosing Patterns and Costs in Patients With Spinal Muscular Atrophy Receiving Disease Modifying Therapies

NCT07378943
View directory record Official record
Conditions
Muscular Atrophy, Spinal
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
4,114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 2, 2026, 2:58 AM EDT
Completed No phase listed Observational

Characteristics, Adherence, and Persistence Among Multiple Sclerosis Patients Treated With Disease-Modifying Therapies

NCT06459232
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 14, 2024 · Synced Oct 2, 2026, 2:58 AM EDT
Completed Not applicable Interventional

Validation of a Shared Decision-Making Tool for Multiple Sclerosis

NCT04122989
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
MS-SUPPORT
Other
Lead sponsor
Shared Decision Making Resources
Other
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Georgetown, Maine
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Oct 2, 2026, 2:58 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS)

NCT03222973
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
BIIB033 (opicinumab), Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 58 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
51
States / cities
Cullman, Alabama • Gilbert, Arizona • Berkeley, California + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Oct 2, 2026, 2:58 AM EDT
Completed No phase listed Observational

Impact of Fingolimod Adherence on Outcomes

NCT05141669
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Fingolimod
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
694 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Oct 2, 2026, 2:58 AM EDT
Recruiting Phase 3 Interventional

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

NCT04047628
View directory record Official record
Conditions
Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Best Available Therapy (BAT)
Procedure · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
23
States / cities
Palo Alto, California • Aurora, Colorado • Evanston, Illinois + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 2, 2026, 2:58 AM EDT
Completed Phase 3 Interventional Results available

A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

NCT02637856
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Ocrelizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
608 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
67
States / cities
Cullman, Alabama • Phoenix, Arizona • Tucson, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated May 26, 2020 · Synced Oct 2, 2026, 2:58 AM EDT
Completed No phase listed Observational

Characteristics and Treatment Patterns of Patients With Sickle Cell Disease in Globin Research Network for Data and Discovery Registry

NCT06662812
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Not listed
Lead sponsor
Novartis
Industry
Eligibility
Not listed
Enrollment
1,665 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Oct 2, 2026, 2:58 AM EDT
Completed No phase listed Observational Results available

Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS): Extension of the DISCOMS Study

NCT04754542
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
55 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
10
States / cities
Aurora, Colorado • Kansas City, Kansas • New York, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Oct 2, 2026, 2:58 AM EDT
Active, not recruiting No phase listed Observational

A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies

NCT05688436
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Diroximel Fumarate, Alemtuzumab, Fingolimod, Glatiramer acetate, Interferon beta, Natalizumab, Ocrelizumab, Ofatumumab, Ozanimod, Peginterferon beta-1a, Ponesimod, Siponimod
Drug · Biological
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
1,178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
1
States / cities
Eden Prairie, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 2, 2026, 2:58 AM EDT
Completed Phase 3 Interventional Results available

Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy

NCT05028634
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Interventions
Tetanus, diphtheria, and acellular pertussis vaccine, Pneumococcal polysaccharide vaccine, Seasonal influenza vaccine
Biological
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
29
States / cities
Palo Alto, California • Colorado Springs, Colorado • Southington, Connecticut + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Oct 2, 2026, 2:58 AM EDT
Completed Phase 4 Interventional

Natalizumab Temporary Discontinuation Study

NCT02775110
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Natalizumab discontinuation
Other
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Oct 2, 2026, 2:58 AM EDT
Recruiting No phase listed Observational

Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease

NCT06941389
View directory record Official record
Conditions
Sickle Cell Disease (SCD)
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
3 Years to 20 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
31
States / cities
Birmingham, Alabama • Wilmington, Delaware • Washington D.C., District of Columbia + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 2, 2026, 2:58 AM EDT
Completed No phase listed Observational

Analysis of Lymphocyte Cell Surface Adhesion Marker Expression in Natalizumab Population With Active Control

NCT01626248
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
John F. Foley, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 14, 2013 · Synced Oct 2, 2026, 2:58 AM EDT
Completed Phase 4 Interventional Results available

A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis

NCT01216072
View directory record Official record
Conditions
Relapsing Forms of Multiple Sclerosis
Interventions
Fingolimod, Standard MS DMTs
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,053 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
142
States / cities
Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 125 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Oct 2, 2026, 2:58 AM EDT
Active, not recruiting Phase 4 Interventional

A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation

NCT05090371
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
Ofatumumab, Disease modifying treatment (DMT)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
37
States / cities
Birmingham, Alabama • Cullman, Alabama • Chandler, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 2, 2026, 2:58 AM EDT